Mirum Pharmaceuticals Inc (NAS:MIRM)
$ 41.56 -0.47 (-1.12%) Market Cap: 2.02 Bil Enterprise Value: 2.06 Bil PE Ratio: 0 PB Ratio: 8.69 GF Score: 51/100

Mirum Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2024 / 06:30PM GMT
Release Date Price: $26.26 (-5.91%)
Jess Fye JPMorgan;Analyst

Great, good morning, everyone. Welcome. I'm Jess Fye, senior biotech analyst at JPMorgan. And we're continuing the 42nd Annual Healthcare Conference today with Mirum.

I'm joined on stage by the company's CEO, Chris Peetz. He's going to give a presentation on the business and then we're going to go into Q&A. If you want to ask a question in the room, you can raise your hands, and we'll bring you a microphone or you can submit them via the portal. So with that, let me pass over to Chris.

Chris Peetz Mirum Pharmaceuticals
Inc. - President & CEO

Thanks, Jess, and thanks for hosting us here today. Really excited to give you an update on Mirum, and introduction for those not familiar. And quick note that we'll be making forward-looking statements in the presentation, so I refer you to our SEC filings for a more complete disclosure of risk factors.

Mirum is a commercial rare disease company with a leading position in pediatric hepatology, took dramatic steps forward in building out both the operating scale

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot